Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2022-06-17

FDA Approved: SUBLOCADE — Supplemental Application (Indivior Inc.)

View source ↗

Summary

The FDA approved a supplemental application for SUBLOCADE (buprenorphine) submitted by Indivior Inc., resulting in updated labeling for the product.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • SUBLOCADE (buprenorphine extended-release)

Snippet

SUPPL AP for SUBLOCADE (BUPRENORPHINE)